The pharmaceutical industry in Pakistan is a very vital sector of the national healthcare and industrial development, but has structural and regulatory bottlenecks that restrict the growth of the pharmaceutical industry as well as competitiveness in exports. The lack of innovation and foreign investment is restricted by overdependence on imported raw materials, poor adherence to international standards, and inconsistent pricing policies. Although the digitisation of approvals and deregulation of the non-essential prices of drugs like DRAP are positive moves, the industry is still in need of structural improvement in terms of quality infrastructure, localisation of API, and facilitation of exports as a way of realising the full potential of the sector and making it grow sustainably.
Skip to content
Skip to footer
